Aspire Private Capital LLC Purchases New Position in Boston Scientific Corporation $BSX

Aspire Private Capital LLC acquired a new position in Boston Scientific Corporation (NYSE:BSX) in the 1st quarter, HoldingsChannel.com reports. The fund acquired 20,806 shares of the medical equipment provider’s stock, valued at approximately $1,306,000.

A number of other hedge funds have also bought and sold shares of the business. Renaissance Group LLC purchased a new position in shares of Boston Scientific in the fourth quarter valued at $28,064,000. Rathbones Group PLC lifted its holdings in Boston Scientific by 20.9% during the 4th quarter. Rathbones Group PLC now owns 2,759,657 shares of the medical equipment provider’s stock worth $263,133,000 after purchasing an additional 477,680 shares in the last quarter. Tounjian Advisory Partners LLC bought a new position in Boston Scientific in the 4th quarter worth about $1,477,000. Waycross Partners LLC bought a new position in Boston Scientific in the 4th quarter worth about $2,384,000. Finally, Kepler Cheuvreux Suisse SA purchased a new position in Boston Scientific during the 3rd quarter valued at about $26,955,000. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on BSX shares. Robert W. Baird set a $70.00 price target on shares of Boston Scientific in a report on Thursday, May 28th. Wells Fargo & Company reaffirmed an “equal weight” rating and set a $55.00 price objective (down from $75.00) on shares of Boston Scientific in a research note on Thursday, May 28th. Wall Street Zen lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a report on Saturday, March 28th. Royal Bank Of Canada reiterated an “outperform” rating on shares of Boston Scientific in a research note on Thursday, May 28th. Finally, Barclays cut their price target on shares of Boston Scientific from $96.00 to $89.00 and set an “overweight” rating for the company in a report on Thursday, May 28th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Boston Scientific currently has an average rating of “Moderate Buy” and a consensus price target of $83.36.

Boston Scientific Stock Down 0.1%

Shares of NYSE BSX opened at $44.16 on Monday. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42. The business has a 50-day moving average of $52.87 and a 200-day moving average of $70.97. The firm has a market capitalization of $65.64 billion, a price-to-earnings ratio of 18.48, a PEG ratio of 0.85 and a beta of 0.56. Boston Scientific Corporation has a 12 month low of $43.89 and a 12 month high of $109.50.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The business had revenue of $5.20 billion for the quarter, compared to the consensus estimate of $5.19 billion. During the same period last year, the firm posted $0.75 earnings per share. Boston Scientific’s quarterly revenue was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Sell-side analysts expect that Boston Scientific Corporation will post 3.36 earnings per share for the current fiscal year.

Boston Scientific announced that its board has authorized a share buyback program on Monday, May 18th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical equipment provider to buy up to 6.4% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s board of directors believes its stock is undervalued.

Insider Activity

In other news, Director Cheryl Pegus bought 1,770 shares of Boston Scientific stock in a transaction that occurred on Wednesday, May 20th. The shares were acquired at an average price of $56.49 per share, with a total value of $99,987.30. Following the completion of the purchase, the director directly owned 1,770 shares in the company, valued at $99,987.30. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director David C. Habiger purchased 2,250 shares of the stock in a transaction on Wednesday, May 20th. The shares were purchased at an average price of $55.92 per share, for a total transaction of $125,820.00. Following the transaction, the director directly owned 13,878 shares of the company’s stock, valued at approximately $776,057.76. This represents a 19.35% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders have purchased 9,800 shares of company stock worth $554,012. 0.34% of the stock is currently owned by corporate insiders.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.